On April 23, 2019 Zetagen Therapeutics, Inc., a private, US-based biotechnology company dedicated to driving breakthrough innovation in the treatment of metastatic bone cancers and osteologic interventions, reported that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 102656437 to the Company (Press release, Zetagen Therapeutics, APR 23, 2019, View Source [SID1234643688]). This patent, entitled Neurogenic Regulation of Bone Growth and Bone Degradation, covers the use of methods for promoting controlled bone creation and destruction as a means to repair large bone segmental defects. This patent follows the previously issued U.S. Patent No. 10208306 and South African PCT. 2017/00029 covering the use of a method for stimulating bone growth using a small molecule.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This latest patent issuance is a significant piece of our Global IP Strategy. This provides the opportunity to further develop our therapies to aid patients afflicted by metastatic lesions," said Joe C. Loy, CEO of Zetagen Therapeutics, Inc.

The new patent is part of an expanding and comprehensive portfolio of patents, patent applications and other intellectual property covering the composition, synthesis, manufacturing, formulations and uses for the treatment of a variety of metastatic bone lesions and osteologic interventions. Zetagen exclusively licensed its platform technology from the State University of New York in 2016.